Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk faces US Senate committee
Novo Nordisk Stock Slips as CEO Faces Senate Inquiry Into Wegovy, Ozempic Prices
Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.
Novo Nordisk faces US congressional grilling over price of weight loss drugs, FT reports
Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of blockbuster diabetes and weight loss drugs, as Ozempic falls into the scope of U.
Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
Novo Nordisk CEO Lars Fruergaard Jørgensen faces a Senate hearing led by Bernie Sanders over the high cost of Ozempic and Wegovy, as U.S. lawmakers push for drug price reductions.
Novo Nordisk's Experimental Oral Drug Reports 'Remarkable' Weight Loss, Early Data Shows
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain,
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,
Novo Nordisk faces US Senate committee grilling over price of weight loss drugs
was $468 now $279 for your first year. Make up your own mind. Build robust opinions with the FT’s trusted journalism. Offer available here until 24th October.
Senate HELP Committee hearing could get heated as Novo Nordisk CEO testifies
A Senate Committee on Health, Education, Labor and Pension hearing scheduled for Tuesday has all the makings of a showdown as Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is set to be the sole witness to testify about the drugmaker's prices for the diabetes and weight loss drugs Ozempic and Wegovy.
Novo Nordisk, Denmark
Novo Nordisk is bigger than Denmark's economy — but the prime minister isn't worried about another Nokia
Denmark Prime Minister Mette Frederiksen downplayed concerns that Ozempic maker Novo Nordisk (NVO), the Scandinavian nation’s largest corporation, could someday drag down its economy the way the once-dominant Nokia (NOK) did to Finland in the 2000s.
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
But Danish prime minister Mette Frederiksen isn't worried about a 'Nokia risk' from pharma giant.
Denmark’s PM Downplays Concerns Over Novo Nordisk’s Dominance Amid Economic Growth Surge
Denmarks Prime Minister, Mette Frederiksen, rejected concerns over the economic risks posed by Novo Nordisks rapid growth. Despite comparisons to Finlands past dependence on Nokia, Frederiksen highlighted Denmarks
Morningstar
9h
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
New public and private entrants are emerging to challenge the leading positions of
Novo
Nordisk
NVO and Eli Lilly LLY in ...
1d
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% ...
3d
on MSN
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
3d
on MSN
Novo Nordisk Sinks on Obesity Drug Study's Disappointing Results
Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest ...
3d
on MSN
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
17h
Preço do Ozempic fica mais difícil para Novo Nordisk justificar
O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...
11h
Novo CEO to blame drug middlemen
The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...
FiercePharma
11h
Warren, others urge government to allow generics to Novo's blockbuster GLP-1s ahead of CEO hearing
Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ozempic
Wegovy
Denmark
Bernie Sanders
United States
Feedback